Roche Oncology is dedicated to improving patient care by developing novel medicines for the treatment and management of different-type of cancers. Research and Development in the disease area of oncology aims to provide effective cancer therapies through the discovery and development of novel therapeutics that target the specific molecular pathways associated with cancer.
Traditionally, anti-cancer drugs have been largely non-specific, and frequently directed against general processes rather than against tumor-specific molecular targets. Although efficacious, these agents are limited, not only by low response rates but by narrow safety margins. Tumor biology is driven by an iterative process of mutation and selection that results in the acquisition of multiple novel properties by the malignant cells.
Therefore, the future of cancer therapy will rely on the choice of the most appropriate combination of drugs for patients, based on the genetic profile of their tumor. The realisation of such "personalised cancer care" through rational integration of diagnostics and therapeutics is a major focus of Roche Oncology and Diagnostics. This fitting of treatment to patients is the foundation for Personalized Healthcare (PHC) which represents a major change in our approach to healthcare.
PHC is already happening – the key enabler is a new model for research and development which uses the combined expertise of Pharma and Diagnostics throughout the value chain.
Much remains to be done to usher in the era of Personalized Healthcare. It is not easy and it will take time. In terms of the benefits to patients and the future of our industry, it is the right and the only way to move forward.
While PHC will be a long-term commitment, requiring patience and perseverance, we also need to bring a greater sense of urgency to our activities in this field.
With our expertise in diagnostics, genetics/genomics and drug discovery, Roche is uniquely positioned to continue to drive this trend in oncology and expand our leadership in the field.
This strategy of Oncology at Roche will allow the company to focus discovery efforts on areas where we can provide first-in-class small molecules or novel biologicals — to enhance development through tailored preclinical and clinical profiling.
Oncology product portfolio:
Please note that Roche is unable to answer questions on individual disease treatment / management matters. These should be discussed with your doctor. As product information and availability varies from country to country, we are able to respond to Pakistan enquiries only. We cannot answer product-related questions through this website.
Xeloda® (capecitabine) is a cytostatic agent and is available as tablets. Xeloda is a fluoropyrimidine carbamate derivative that was designed as an orally administered, tumour-activated and tumour-selective cytotoxic agent. Xeloda is indicated in locally advanced or metastatic breast cancer. Xeloda is indicated as adjuvant treatment of colon as well as for patients with metastatic colorectal cancer. Xeloda is indicated as first-line treatment of patients with advanced oesophagogastric cancer. Xeloda is also indicated as adjuvant treatment of patients following complete resection of stage II and III gastric adenocarcinoma.
HERCEPTIN® (trastuzumab) is an anti-neoplastic agent and is available as powder for concentrate for solution for infusion. Herceptin is a recombinant humanised monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Herceptin is indicated for the treatment of HER2+ve breast cancer (both metastatic and early breast cancer) and HER2 +ve advanced gastric cancer (AGC).
AVASTIN® (bevacizumab) is an anti-neoplastic agent and is available as concentrate for solution for infusion. Avastin is a recombinant humanised monoclonal antibody that selectively binds to and neutralises the biologic activity of human vascular endothelial growth factor (VEGF). Avastin is approved for the treatment of metastatic colorectal cancer (mCRC), locally recurrent or metastatic breast cancer (mBC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer (mRCC), malignant glioma (WHO Grade IV) – glioblastoma, epithelial ovarian, fallopian tube and primary peritoneal cancer and persistent, recurrent, or metastatic carcinoma of the cervix.
- RISTOVA (RA)
Ristova® (rituximab) is an anti-neoplastic agent and is available as concentrate for solution for infusion. Ristova is a chimeric mouse/human monoclonal antibody that binds specifically to the transmembrane antigen CD20. Rituximab binds to the CD20 antigen on B-lymphocytes and initiates immunologic reactions that mediate B-cell lysis. Ristova® (rituximab) is indicated for the treatment of patients with CD20+ve non-hodgkin’s lymphoma (NHL) & chronic lymphocytic leukemia (CLL).
Tarceva® (erlotinib) is antineoplastic agent and is available as film-coated tablets. Tarceva potently inhibits the intracellular phosphorylation of HER1 (human epidermal growth factor receptor 1 protein)/EGFR (epidermal growth factor receptor). Inhibition of EGFR phosphotyrosine results in cell stasis and/or death. Tarceva is indicated for the first-line and maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Tarceva is indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Tarceva is also indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.